Search
Now showing items 1-2 of 2
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network
(Journal of the American Heart Association, 2019-05-07)
Background-PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low-density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high-risk patients. We used ...
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance
(Molecular Metabolism, 2023-01-13)
Objective: Oxidative stress contributes to the development of insulin resistance (IR) and atherosclerosis. Peroxidation of lipids produces reactive dicarbonyls such as Isolevuglandins (IsoLG) and malondialdehyde (MDA) that ...